Document is current
Any future updates will be listed below
-
Authors
Ogawa, Yoshiyuki https://orcid.org/0000-0003-1459-3970
Amano, Kagehiro
Matsuo-Tezuka, Yukari
Okada, Norihiro
Murakami, Yoichi
Nakamura, Takao
Yamaguchi-Suita, Haruko
Nogami, Keiji
-
Funding
Funding for this research was provided by:
Chugai Pharmaceutical
- License Information
-
More Information
Article History
Received: 22 July 2022
Revised: 4 October 2022
Accepted: 5 October 2022
First Online: 4 November 2022
Declarations
:
: Y. O, K. A. and K. N. received fees for their contribution to the development of this article or supplement from Chugai Pharmaceutical Co., Ltd. Outside of this article, K. A. received consultancy or advisory role and speakers bureau from Chugai Pharmaceutical Co., Ltd., and research funding and speakers Bureau for KM Biologics Co., Ltd., and speakers bureau for Bioverativ Inc., Bayer A/G, Shire Plc, Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Novo Nordisk A/S, CSL Behring, and Pfizer Inc., and Japan Blood Products Organization. Y. M. T.<b>,</b> N. O.<b>,</b> Y. M., T. N., and H. Y. S. are current employees of Chugai Pharmaceutical Co., Ltd. K. N. received grants or contracts, payment or honoraria, speakers bureau for Takeda Pharmaceutical Co., Ltd., Sanofi S.A., CSL Behring, Chugai Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., Bayer A/G, Novo Nordisk A/S, and KM Biologics Co., Ltd.
